Biopharmaceutical company focusing on novel treatments for rare diseases.
Traws Pharma, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to advancing small molecule oral therapies for respiratory viral diseases and oncological conditions. The company's research and development efforts are centered on pioneering treatments designed to combat treatment resistance in diseases such as influenza and COVID-19. Key investigational products include TRX01 (travatrelvir), an Mpro/3CL inhibitor tailored for COVID-19 treatment, and TRX100 (viroxavir), an endonuclease inhibitor aimed at addressing pandemic influenza.
Founded in 1998 and headquartered in Newtown, Pennsylvania, Traws Pharma was previously known as Onconova Therapeutics, Inc. before rebranding in April 2024. The company's commitment extends to oncology with narazaciclib, a Phase 1/2 clinical trial candidate targeting CDK4/6 kinases in cancer patients, including those with endometrial cancer. Additionally, Traws Pharma explores the potential of oral rigosertib, either alone or in combination therapies, across various cancer types, showcasing its broad therapeutic approach.
With a strategic focus on innovative drug development and therapeutic innovation, Traws Pharma collaborates extensively with scientific partners and healthcare professionals. By leveraging its deep expertise and robust pipeline, the company aims to deliver impactful treatments that improve patient outcomes and address critical unmet medical needs in global healthcare markets.